Key Takeaways
- • Great Point Partners, a Greenwich-based healthcare-focused private investment firm, acquired a majority stake in Lenis Group, a Slovenian specialty pharmaceutical commercialization and distribution company, in December 2025.
- • Lenis Group operates across Central and Eastern Europe (CEE), providing full-service commercialization and distribution services for niche and specialty prescription medicines, with capabilities spanning early access, pre-launch, launch, growth, and lifecycle management phases.
- • The transaction included a commitment to regional expansion and strengthening senior leadership, with Michel Vounatsos, former Biogen CEO, appointed as Board Chairman as part of the investment.
- • Lenis Group's existing management team will remain operational on a day-to-day basis, ensuring continuity while benefiting from GPP's healthcare sector expertise and expansion capital.
- • The deal reflects continued private equity activity in specialty pharmacy and pharmaceutical services, a sector experiencing increased investment as PE firms pursue healthcare platform consolidation and international expansion opportunities.
Summary
Great Point Partners ("GPP"), a Greenwich, Connecticut-based private investment firm with exclusive focus on the healthcare industry, announced its acquisition of a majority stake in Lenis Group in December 2025. Lenis Group is a fast-growing, Ljubljana-based full-service specialty pharmaceutical commercialization and distribution company serving the Central and Eastern Europe region.
Founded in 2008, Lenis has established itself as a regional partner to biotechnology and pharmaceutical companies across the complex CEE market. The company provides comprehensive services across the entire product lifecycle, including early access programs, pre-launch preparation, commercial launch support, growth phase management, and mature lifecycle management for niche and specialty prescription medicines. The company is recognized for its strong compliance culture, market access expertise, reimbursement capabilities, regulatory knowledge, and high-quality medical and marketing functions, supported by its direct regional presence and cross-functional operational teams embedded in local markets.
As part of the investment structure, Lenis Group's existing management team committed to remain in operational roles. GPP is allocating significant resources toward the company's ambitious regional expansion strategy and strengthening its senior leadership infrastructure. A key component of the investment included appointing Michel Vounatsos, the former Chief Executive Officer of Biogen, to serve as Board Chairman—bringing substantial industry experience and relationships to the platform.
The transaction aligns with broader private equity investment trends in healthcare services and specialty pharmacy, where firms are pursuing platform consolidation, geographic expansion, and operational leverage. Lenis Group's regional specialization, regulatory expertise, and established relationships with healthcare institutions, regulatory authorities, NGOs, and patient organizations position it as a foundation for potential add-on acquisitions or expanded service offerings across CEE markets. The investment reflects GPP's strategic focus on healthcare infrastructure businesses with recurring revenue models and operational complexity that benefit from financial resources and governance support.
Founded in 2008, Lenis has established itself as a regional partner to biotechnology and pharmaceutical companies across the complex CEE market. The company provides comprehensive services across the entire product lifecycle, including early access programs, pre-launch preparation, commercial launch support, growth phase management, and mature lifecycle management for niche and specialty prescription medicines. The company is recognized for its strong compliance culture, market access expertise, reimbursement capabilities, regulatory knowledge, and high-quality medical and marketing functions, supported by its direct regional presence and cross-functional operational teams embedded in local markets.
As part of the investment structure, Lenis Group's existing management team committed to remain in operational roles. GPP is allocating significant resources toward the company's ambitious regional expansion strategy and strengthening its senior leadership infrastructure. A key component of the investment included appointing Michel Vounatsos, the former Chief Executive Officer of Biogen, to serve as Board Chairman—bringing substantial industry experience and relationships to the platform.
The transaction aligns with broader private equity investment trends in healthcare services and specialty pharmacy, where firms are pursuing platform consolidation, geographic expansion, and operational leverage. Lenis Group's regional specialization, regulatory expertise, and established relationships with healthcare institutions, regulatory authorities, NGOs, and patient organizations position it as a foundation for potential add-on acquisitions or expanded service offerings across CEE markets. The investment reflects GPP's strategic focus on healthcare infrastructure businesses with recurring revenue models and operational complexity that benefit from financial resources and governance support.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.